α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy A. Cole, Hien Zhao, Timothy J. Collier et al. · JCI Insight · 2021
Full textCC BY
Clinical Neurology
Filters2 filters applied
Status
- No notice
- From publisher notices and Retraction Watch. Not checked means nobody has looked yet.
Year
Readable here
Study type
Licence
Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up
Nelly Kanberg, Joel Simrén, Arvid Edén et al. · EBioMedicine · 2021
Abstract only
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact
Hannah E. Davis, Gina S. Assaf, Lisa McCorkell et al. · eClinicalMedicine · 2021
Abstract only
Cognitive impact of COVID-19: looking beyond the short term
Scott Miners, Patrick G. Kehoe, Seth Love · Alzheimer's Research & Therapy · 2020 · Review
Abstract only
Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease
Javier Pagonabarraga, Idoia Corcuera-Solano, Yolanda Vives-Gilabert et al. · PLoS ONE · 2013
Full textCC BY